Developer docs
API playgroundTry for free, no card

Search company profiles

ImmusanT

Full company profile

uuid0002ikz

Namestring
ImmusanT
Websiteurl
immusant.com
Company typeenum
Private
Founded yearint
2011
Descriptiontext

ImmusanT is a privately held clinical-stage biotechnology company founded in 2011 and headquartered in Cambridge, Massachusetts. The company is focused on developing diagnostics and therapeutics for celiac disease, an autoimmune disorder triggered by gluten ingestion. Its work is centered on immunotherapeutic approaches and diagnostic tools designed to address the underlying immune response rather than symptom management alone. The short description in the firmographics explicitly identifies ImmusanT as a biotechnology company developing diagnostics and therapeutics for the diagnosis and treatment of celiac disease, indicating a single-indication focus and a translational R&D profile rather than a platform business.

The company has raised approximately $72.78 million in private financing across three priced equity rounds between 2011 and 2017, with lead backing from Vatera Healthcare Partners and ARCH Venture Partners; a subsequent 2018 investment from the JDRF T1D Fund points to potential adjacency into type 1 diabetes and related autoimmune indications. Leadership combines the Chief Scientific Officer and Chief Medical Officer roles in a single executive (Bob Anderson), with Maury Matteodo serving as CFO. The organization is small, with 11-50 employees, consistent with a lean clinical-stage operating model. The commercial website currently displays only a verification/loading page, suggesting limited active digital infrastructure or public-facing communications at the time of data capture.

The business model is consistent with a clinical-stage biotech: pre-revenue, dependent on milestone-driven capital raises, and targeting eventual FDA-approved therapeutic and diagnostic products for the celiac disease patient population. There is no disclosed pricing model, GTM motion, customer segmentation, partnership, or licensing revenue in the input data, and the company does not appear to have reached commercialization. As a result, revenue mechanics are entirely prospective, tied to future product launches rather than any current commercial activity.

Short descriptiontext

ImmusanT is a Cambridge, Massachusetts-based clinical-stage biotechnology company founded in 2011 that develops diagnostics and therapeutics for celiac disease, funded by Vatera Healthcare Partners, ARCH Venture Partners, and the JDRF T1D Fund.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
celiac disease therapeutics, immunotherapy vaccine, companion diagnostics, autoimmune disease biotech, epitope-specific treatment
Industry2 codes
SECONDARYHLAAALAK
Autoimmune & Allergy Diagnostics
SECONDARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
NAICS code1 code
  • Medical and Diagnostic Laboratories6215
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Biopharmaceuticals
Social media profiles2 records
Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

ImmusanT is a clinical-stage biotechnology company developing a peptide-based therapeutic vaccine (Nexvax2) and a blood-based companion diagnostic for the treatment and diagnosis of celiac disease. Its products are designed to induce immune tolerance to gluten in genetically susceptible patients and to provide a quantitative, blood-based alternative to current diagnostic methods. The company operates in the autoimmune disease therapeutics market with a focus on antigen-specific immunotherapy.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

No product information available from the source data. The website displayed only a security verification loading page.

Product and service2 records
1Nexvax2
CategoryTherapeutic vaccine / immunotherapy
Description

A peptide-based therapeutic vaccine candidate targeting HLA-DQ2-restricted T-cell responses in celiac disease, designed to induce immune tolerance to gluten in genetically susceptible patients. Intended for adult celiac disease patients who continue to experience symptoms despite adherence to a gluten-free diet.

2Blood-based companion diagnostic for celiac disease
CategoryCompanion diagnostic
Description

A blood-based diagnostic test developed to detect and monitor celiac disease, intended to serve as a quantitative alternative to biopsy-based diagnosis and as a patient stratification and monitoring tool alongside ImmusanT's therapeutic vaccine.

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Major immunology-focused pharmaceutical company with deep autoimmune franchise (Humira/Skyrizi/Rinvoq). Acquired Alvine Pharmaceuticals (celiac-focused) and represents both a competitive threat and likely acquirer for celiac assets.

TypeEmerging player
Description

Clinical-stage immunology company developing therapeutics for autoimmune and inflammatory diseases. Comparable as a focused immunology/biotech peer operating in adjacent autoimmune indications.

TypeDirect peer
Description

Autoimmune therapeutics company developing disease-modifying therapies in immunology, including T1D and celiac-adjacent indications. Comparable in focus on autoimmune disease modification at clinical stage.

TypeDirect peer
Description

Clinical-stage immunology company developing antigen-specific tolerance therapies for autoimmune diseases, including celiac. Highly comparable to ImmusanT in modality (tolerogenic immunotherapy) and target disease.

TypeDirect peer
Description

Celiac-focused spin-out from Selecta Biosciences developing antigen-specific tolerance therapy for celiac disease. Closely comparable to ImmusanT in indication and modality.

TypeEmerging player
Description

Developer of nanoparticle-based antigen-specific tolerance therapies for autoimmune indications. Comparable platform technology direction to ImmusanT's peptide-based tolerance approach.

7Selecta Biosciences
TypeDirect peer
Description

Pioneer in antigen-specific tolerance and tolerogenic immunotherapies; acquired Kanyos Bio (celiac-focused). Comparable to ImmusanT in tolerogenic vaccine approach for autoimmune disease.

TypeDirect peer
Description

Developer of antigen-specific immune tolerance therapies (Tregitope-based platform) with celiac disease as a lead indication. Directly comparable to ImmusanT in therapeutic modality and indication focus.

TypeBroad incumbent
Description

Global pharmaceutical company with a strong gastroenterology and rare disease franchise. Has pursued celiac disease assets and represents the strategic-acquirer / incumbent competitive landscape for celiac therapies.

TypeDirect peer
Description

Historical celiac-disease focused biopharmaceutical (acquired by AbbVie). Developed ALV003 (latiglutenase), a celiac digestive enzyme therapeutic — the most direct historical celiac competitor to ImmusanT's pipeline.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ImmusanT

Biopharmaceuticalsimmusant.com

ImmusanT is a Cambridge, Massachusetts-based clinical-stage biotechnology company founded in 2011 that develops diagnostics and therapeutics for celiac disease, funded by Vatera Healthcare Partners, ARCH Venture Partners, and the JDRF T1D Fund.

What ImmusanT does

ImmusanT is a privately held clinical-stage biotechnology company founded in 2011 and headquartered in Cambridge, Massachusetts. The company is focused on developing diagnostics and therapeutics for celiac disease, an autoimmune disorder triggered by gluten ingestion. Its work is centered on immunotherapeutic approaches and diagnostic tools designed to address the underlying immune response rather than symptom management alone. The short description in the firmographics explicitly identifies ImmusanT as a biotechnology company developing diagnostics and therapeutics for the diagnosis and treatment of celiac disease, indicating a single-indication focus and a translational R&D profile rather than a platform business.

The company has raised approximately $72.78 million in private financing across three priced equity rounds between 2011 and 2017, with lead backing from Vatera Healthcare Partners and ARCH Venture Partners; a subsequent 2018 investment from the JDRF T1D Fund points to potential adjacency into type 1 diabetes and related autoimmune indications. Leadership combines the Chief Scientific Officer and Chief Medical Officer roles in a single executive (Bob Anderson), with Maury Matteodo serving as CFO. The organization is small, with 11-50 employees, consistent with a lean clinical-stage operating model. The commercial website currently displays only a verification/loading page, suggesting limited active digital infrastructure or public-facing communications at the time of data capture.

The business model is consistent with a clinical-stage biotech: pre-revenue, dependent on milestone-driven capital raises, and targeting eventual FDA-approved therapeutic and diagnostic products for the celiac disease patient population. There is no disclosed pricing model, GTM motion, customer segmentation, partnership, or licensing revenue in the input data, and the company does not appear to have reached commercialization. As a result, revenue mechanics are entirely prospective, tied to future product launches rather than any current commercial activity.

ImmusanT firmographics

Firmographics
Name
ImmusanT
Website
https://immusant.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
11–50 employees
Short description
ImmusanT is a Cambridge, Massachusetts-based clinical-stage biotechnology company founded in 2011 that develops diagnostics and therapeutics for celiac disease, funded by Vatera Healthcare Partners, ARCH Venture Partners, and the JDRF T1D Fund.
Ownership category
akta.pro rank

Where ImmusanT is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Markets served

ImmusanT business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

ImmusanT product offering

Product offering

Core offering

ImmusanT is a clinical-stage biotechnology company developing a peptide-based therapeutic vaccine (Nexvax2) and a blood-based companion diagnostic for the treatment and diagnosis of celiac disease. Its products are designed to induce immune tolerance to gluten in genetically susceptible patients and to provide a quantitative, blood-based alternative to current diagnostic methods. The company operates in the autoimmune disease therapeutics market with a focus on antigen-specific immunotherapy.

Product overview

No product information available from the source data. The website displayed only a security verification loading page.

Differentiator

Problem solved

Functional benefit

Products and services

  • Nexvax2 A peptide-based therapeutic vaccine candidate targeting HLA-DQ2-restricted T-cell responses in celiac disease, designed to induce immune tolerance to gluten in genetically susceptible patients. Intended for adult celiac disease patients who continue to experience symptoms despite adherence to a gluten-free diet.
  • Blood-based companion diagnostic for celiac disease A blood-based diagnostic test developed to detect and monitor celiac disease, intended to serve as a quantitative alternative to biopsy-based diagnosis and as a patient stratification and monitoring tool alongside ImmusanT's therapeutic vaccine.

Companies that use ImmusanT

Customer profile

Ideal customer profiles2 records

ImmusanT technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

ImmusanT partnerships and signals

Strategic signal

Recent moves3 records

Expansion highlights3 records

ImmusanT competitors and assessment

Company assessment

Broad incumbents

  • AbbVie: Major immunology-focused pharmaceutical company with deep autoimmune franchise (Humira/Skyrizi/Rinvoq). Acquired Alvine Pharmaceuticals (celiac-focused) and represents both a competitive threat and likely acquirer for celiac assets.
  • Takeda Pharmaceutical: Global pharmaceutical company with a strong gastroenterology and rare disease franchise. Has pursued celiac disease assets and represents the strategic-acquirer / incumbent competitive landscape for celiac therapies.

Emerging players

  • AnaptysBio: Clinical-stage immunology company developing therapeutics for autoimmune and inflammatory diseases. Comparable as a focused immunology/biotech peer operating in adjacent autoimmune indications.
  • Topas Therapeutics: Developer of nanoparticle-based antigen-specific tolerance therapies for autoimmune indications. Comparable platform technology direction to ImmusanT's peptide-based tolerance approach.

Direct peers

  • Provention Bio: Autoimmune therapeutics company developing disease-modifying therapies in immunology, including T1D and celiac-adjacent indications. Comparable in focus on autoimmune disease modification at clinical stage.
  • Anokion: Clinical-stage immunology company developing antigen-specific tolerance therapies for autoimmune diseases, including celiac. Highly comparable to ImmusanT in modality (tolerogenic immunotherapy) and target disease.
  • Kanyos Bio: Celiac-focused spin-out from Selecta Biosciences developing antigen-specific tolerance therapy for celiac disease. Closely comparable to ImmusanT in indication and modality.
  • Selecta Biosciences: Pioneer in antigen-specific tolerance and tolerogenic immunotherapies; acquired Kanyos Bio (celiac-focused). Comparable to ImmusanT in tolerogenic vaccine approach for autoimmune disease.
  • Cour Pharmaceuticals: Developer of antigen-specific immune tolerance therapies (Tregitope-based platform) with celiac disease as a lead indication. Directly comparable to ImmusanT in therapeutic modality and indication focus.
  • Alvine Pharmaceuticals: Historical celiac-disease focused biopharmaceutical (acquired by AbbVie). Developed ALV003 (latiglutenase), a celiac digestive enzyme therapeutic — the most direct historical celiac competitor to ImmusanT's pipeline.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

ImmusanT social profiles

Digital presence

ImmusanT financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ImmusanT leadership team

Management profile

Number of profiles

Profiles2 records

ImmusanT funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ImmusanT M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ImmusanT

What does ImmusanT do?

ImmusanT is a clinical-stage biotechnology company developing a peptide-based therapeutic vaccine (Nexvax2) and a blood-based companion diagnostic for the treatment and diagnosis of celiac disease. Its products are designed to induce immune tolerance to gluten in genetically susceptible patients and to provide a quantitative, blood-based alternative to current diagnostic methods. The company operates in the autoimmune disease therapeutics market with a focus on antigen-specific immunotherapy.

Is ImmusanT a public or private company?

ImmusanT is a private company. It is classified as venture growth investor backed and is currently operating.

When was ImmusanT founded?

ImmusanT was founded in 2011. It employs 11 to 50 people.

Where is ImmusanT based?

ImmusanT is headquartered in Cambridge, United States, in the North America region.

Who are ImmusanT's main competitors?

Broad incumbents on record are AbbVie and Takeda Pharmaceutical. Emerging players are AnaptysBio and Topas Therapeutics. Direct peers are Provention Bio, Anokion, Kanyos Bio, Selecta Biosciences, Cour Pharmaceuticals and Alvine Pharmaceuticals.

Does ImmusanT have an API?

No public API is recorded for ImmusanT.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Allergic LivingFDA Fast Tracks Therapy That Could Help Celiac Disease Patients Tolerate GlutenThe FDA has granted fast-track designation to NexVax2, an injectable immunotherapy developed by ImmusanT designed to help celiac disease patients tolerate gluten. This status aims to accelerate the development of therapies for patients with specific immune genes who currently rely solely on strict dietary restrictions. ImmusanT is currently recruiting for a Phase 2 trial involving 150 patients across the U.S., Australia, and New Zealand.FinSMEsImmusanT Receives Investment from JDRF T1D Fund - FinSMEsImmusanT, a clinical-stage company developing peptide-based immune therapies, received an undisclosed investment from the JDRF T1D Fund. The company will use the funds to accelerate translation of its celiac disease program into a T1D vaccine candidate. Its lead candidate, Nexvax2, has shown safety and bioactivity in Phase 1 studies for celiac disease.VC News DailyImmusanT Lands $40MImmusanT, a clinical-stage biotech company based in Cambridge, Massachusetts, announced the completion of a $40 million Series C equity financing led by ARCH Venture Partners with participation from Vatera Healthcare Partners. The proceeds will fund a randomized Phase II clinical trial of Nexvax2, the company's therapeutic vaccine for celiac disease, as well as advance its diagnostic biomarker program and platform expansion. Steven Gillis and Thomas Daniel from ARCH Venture Partners will join ImmusanT's Board of Directors as part of the transaction.VC News DailyImmusanT Raises $12M in Series BImmusanT announced a $12 million Series B funding from Vatera Healthcare Partners to support the development of its immunotherapy, Nexvax2, for celiac disease. The company has completed Phase 1b trials, and Phase 2 studies are planned to begin in early 2015.VC News DailyImmusanT Raises $20 Million in Series AImmusanT, a Cambridge, Massachusetts-based biotechnology company, has raised $20 million in Series A financing from Vatera Healthcare Partners to advance development of its immunotherapeutic vaccine Nexvax2 and companion diagnostic for celiac disease. The funding will support the therapeutic and diagnostic development plan through proof-of-concept, with the next clinical trial expected to initiate in early 2012. The vaccine, which has demonstrated safety and tolerability in a Phase 1 study, is designed to tolerize celiac disease patients to gluten by reprogramming disease-causing T-cells.